This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maron, B. J. Articles by Nishimura, R. A. Search for Related Content PubMed PubMed Citation Articles by Maron, B. J. Articles by Nishimura, R. A.

TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY: POINT-COUNTERPOINT

The case for surgery in obstructive hypertrophic cardiomyopathy

Barry J. Maron, MD, FACC^*,*, Joseph A. Dearani, MD, Steve R. Ommen, MD, FACC, Martin S. Maron, MD, Hartzell V. Schaff, MD, FACC, Bernard J. Gersh, MB, MBChB, DPhil, FACC and Rick A. Nishimura, MD, FACC

^* Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Departments of Cardiovascular Surgery and Cardiology, Mayo Clinic, Rochester, Minnesota
Hypertrophic Cardiomyopathy Center, Tufts-New England Medical Center, Boston, Massachusetts

Manuscript received December 18, 2003; accepted April 27, 2004.

^* Reprint requests and correspondence: Dr. Barry J. Maron, The Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, 920 E. 28th Street, Suite 60, Minneapolis, Minnesota 55407 (Email: hcm.maron{at}mhif.org).

Relief of left ventricular (LV) outflow obstruction in patients with hypertrophic cardiomyopathy (HCM) and disabling symptoms refractory to maximum medical management has historically been a surgical problem. Surgical septal myectomy permanently abolishes systolic anterior motion of the mitral valve and mitral regurgitation, while normalizing LV pressures and wall stress. Also, these salutary goals are achieved without encumbering patients with post-procedural devices (e.g., pacemakers or defibrillators) or creating potentially arrhythmogenic substrates, as may occur with alcohol septal ablation. Procedural morbidity and mortality risk with myectomy is similar to, and in some institutions less than those for alcohol septal ablation. Over four decades, reports from numerous centers worldwide have consistently and unequivocably documented the benefits of surgery on hemodynamic and functional state, restoring normal and acceptable quality of life to patients of all ages by largely reversing the complications of heart failure. Long-term survival after myectomy is similar to that of the general population and superior to non-operated patients with obstruction. The LV outflow tract morphology in HCM is heterogeneous and not uncommonly includes congenital anomalies of the mitral valve apparatus for which the surgeon has the flexibility to adapt the repair, often employing an extended myectomy. In the current atmosphere of increasing and perhaps excessive enthusiasm for newer catheter-based interventions, it is a critical time to promote and re-emphasize that surgery is the time-honored (and presently the most effective) treatment strategy for relieving heart failure-related disability resulting from dynamic LV outflow obstruction in HCM, and is the primary treatment option for this subgroup of severely symptomatic drug-refractory patients.

Abbreviations and Acronyms   HCM = hypertrophic cardiomyopathy   LV = left ventricular

This article has been cited by other articles:

				S. E. Whitten Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy: A Potentially Life-Threatening Complication Crit. Care Nurse, October 1, 2008; 28(5): 44 - 52. [Full Text] [PDF]

				P. Sorajja, R. A. Nishimura, S. R. Ommen, C. S. Rihal, B. J. Gersh, and D. R. Holmes Jr Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy: An Invasive Hemodynamic Study J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 552 - 560. [Abstract] [Full Text] [PDF]

				R. T Murphy Bringing the obstruction back into hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1249 - 1250. [Full Text] [PDF]

				N. G. Smedira, B. W. Lytle, H. M. Lever, J. Rajeswaran, G. Krishnaswamy, R. K. Kaple, D. O.W. Dolney, and E. H. Blackstone Current Effectiveness and Risks of Isolated Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy Ann. Thorac. Surg., January 1, 2008; 85(1): 127 - 133. [Abstract] [Full Text] [PDF]

				R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]

				I. Olivotto, S. R. Ommen, M. S. Maron, F. Cecchi, and B. J. Maron Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: Will There Ever Be a Randomized Trial? J. Am. Coll. Cardiol., August 28, 2007; 50(9): 831 - 834. [Abstract] [Full Text] [PDF]

				B. J. Maron Surgical Myectomy Remains the Primary Treatment Option for Severely Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy Circulation, July 10, 2007; 116(2): 196 - 206. [Full Text] [PDF]

				M. A. Fifer Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy Circulation, July 10, 2007; 116(2): 207 - 216. [Full Text] [PDF]

				U. S. Valeti, R. A. Nishimura, D. R. Holmes, P. A. Araoz, J. F. Glockner, J. F. Breen, S. R. Ommen, B. J. Gersh, A. J. Tajik, C. S. Rihal, et al. Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy J. Am. Coll. Cardiol., January 23, 2007; 49(3): 350 - 357. [Abstract] [Full Text] [PDF]

				K. Fujikura, R. Otsuka, A. Kalisz, J. A. Ketterling, Z. Jin, R. R. Sciacca, C. C. Marboe, J. Wang, R. Muratore, E. J. Feleppa, et al. Effects of ultrasonic exposure parameters on myocardial lesions induced by high-intensity focused ultrasound. J. Ultrasound Med., November 1, 2006; 25(11): 1375 - 1386. [Abstract] [Full Text] [PDF]

				C. J Knight Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart, September 1, 2006; 92(9): 1339 - 1344. [Full Text] [PDF]

				L. Salberg Treating Hypertrophic Cardiomyopathy: Two Views J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2146 - 2146. [Full Text] [PDF]

				B. J. Maron, J. A. Dearani, S. R. Ommen, M. S. Maron, B. J. Gersh, and R. A. Nishimura Reply J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2146 - 2147. [Full Text] [PDF]

				S. K. Balaram, M. V. Sherrid, J. J. Derose Jr., Z. Hillel, G. Winson, and D. G. Swistel Beyond Extended Myectomy for Hypertrophic Cardiomyopathy: The Resection-Plication-Release (RPR) Repair Ann. Thorac. Surg., July 1, 2005; 80(1): 217 - 223. [Abstract] [Full Text] [PDF]